Toshiaki Sato

机构：EA Pharma (Japan), Shijonawate Gakuen University · ORCID：0000-0002-0073-3592

发表论文 252 篇 · 总被引 6363 次 · h-index 37

代表论文

• Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment (2024 · Journal of Hematology · 被引 25)
• A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis (2024 · Annals of Hematology · 被引 15)
• Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera (2024 · International Journal of Hematology · 被引 11)
• Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study (2025 · The Lancet Haematology · 被引 9)
• Population Pharmacokinetics‐Pharmacodynamics and Exposure‐Response of Ropeginterferon Alfa‐2b in Chinese and Japanese Patients With Polycythemia Vera (2025 · Pharmacology Research & Perspectives · 被引 9)
• Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b (2024 · Frontiers in Pharmacology · 被引 7)